Article Text

Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside
  1. P. Menaut, DVM1,
  2. J. Landart, DVM1,
  3. S. Behr, DVM, DipECVN2,
  4. D. Lanore, DVM3 and
  5. C. Trumel, DVM, PhD, DipECVCP1
  1. 1 Service de Pathologie Médicale des Carnivores Domestiques, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, 31076 Toulouse Cedex, France
  2. 2 Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hertfordshire SG5 3HR
  3. 3 Clinique Vétérinaire de la Rivière, 1 rue Pierre Loti, 31830 Plaisance du Touch, France
  1. Dr Menaut's present address is Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA
  2. Correspondence to Dr Trumel


The records of 11 dogs with evidence of meningoencephalomyelitis of unknown origin were reviewed. Two of them had had a focal form of the disease and the other nine a disseminated form. The forebrain was involved in five of the nine dogs with disseminated disease, the brainstem in all nine and the cerebellum in one. They had been treated with courses of cytosine arabinoside every three weeks and immunosuppressive doses of prednisolone. Their response to the treatment, in terms of quality of life, was judged by their owners and referring veterinarians to have been excellent in five, good in five and poor in one; their survival times ranged from 78 days to more than 603 days. The cumulative probability of survival at two years was 58·4 per cent. No signs of myelosuppression or other side effects associated with cytosine arabinoside were observed.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.